Company Overview - Zhan Yan Biotechnology Co., Ltd. was established on December 6, 2019, with a registered capital of 61.62 million yuan and is located in Chengdu, Sichuan, China [1] - The company is primarily engaged in the research, production, and sales of biomedical materials, dermatological skincare products, and bioactive raw materials [1] - The controlling shareholder is Zhang Yingting, who directly holds 62.1551% of the company's shares [1] IPO and Financial Performance - Zhan Yan Biotechnology has completed its IPO counseling registration with the Sichuan Securities Regulatory Bureau and plans to list on the Beijing Stock Exchange [1] - The company aims to be listed on the New Third Board by September 2025 [1] - Projected revenues for 2023 and 2024 are 486 million yuan and 597 million yuan, respectively, with net profits of 68.48 million yuan and 73.50 million yuan [2][3] - The gross profit margins for 2023 and 2024 are expected to be 62.33% and 68.34%, respectively [2][3] Shareholding Structure - As of the date of the public transfer prospectus, Zhang Yingting directly holds 62.16% of the shares and, through concerted actions, controls 91.22% of the voting rights [3] - Other shareholders include Yang Fengle, who holds 17.79%, and Hengqin Zhan Yan, an employee stock ownership platform, which holds 11.28% [3] - Wang Kun directly holds 4.06% and indirectly holds 0.24%, while Tax Ke Ying directly holds 0.41% and indirectly holds 0.31% [4] Management Team - Zhang Yingting serves as the Chairman and Manager of the company [5] - Wang Kun is the Director and Deputy Manager, while Tax Ke Ying is the Secretary of the Board and Chief Financial Officer [5] - The management team has extensive experience in the pharmaceutical and biotechnology sectors, with backgrounds in various companies prior to joining Zhan Yan Biotechnology [6][7][8]

Group 1 - The core viewpoint of the news is that Zhan Yan Biotechnology Co., Ltd. has completed its IPO counseling record with the Sichuan Securities Regulatory Bureau and plans to list on the Beijing Stock Exchange, with China International Capital Corporation as the counseling institution [1] - Zhan Yan Biotechnology was established on December 6, 2019, with a registered capital of 61.62 million yuan, focusing on the research, production, and sales of biomedical materials, dermatological skincare products, and bioactive raw materials [1] - The company has three major sub-brands: "Zhan Yan" for skin issues, "Zhan Xiao Yan" for infant skincare, and "De Fei Lin" for bioactive composite acids, targeting different demographics with product lines for skin disease auxiliary treatment and sensitive skin repair [2] Group 2 - The projected operating revenue for Zhan Yan Biotechnology is 486 million yuan in 2023 and 597 million yuan in 2024, with net profits of 68.48 million yuan and 73.50 million yuan respectively, and gross profit margins of 62.33% and 68.34% [2][3] - In 2024, the company expects to achieve an operating revenue of 597.47 million yuan and a net profit of 73.50 million yuan, with a gross profit margin of 68.34% and a weighted return on net assets of 22.39% [3] - Zhang Yingting, the controlling shareholder, directly holds 62.16% of the company's shares and, along with his associates, controls 91.22% of the voting rights [3]

Group 1 - The core viewpoint of the article is that Zhan Yan Biotechnology Co., Ltd. has initiated the listing guidance process with the support of China International Capital Corporation [1] - Zhan Yan Biotechnology was established on December 6, 2019, with a registered capital of 61.62 million yuan [1] - The legal representative of the company is Zhang Yingting, who is also the controlling shareholder, holding 62.1551% of the company's equity [1] Group 2 - The company specializes in the research, production, and sales of biomedical materials, dermatological skincare products, and biological raw materials [1] - Zhan Yan has developed several brands, including the dermatological repair brand Zhan Yan, the infant skincare brand Zhan Xiao Yan, and the brand Defilin [1]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][29]. Core Insights - The report highlights significant market performance for the week of June 23-27, 2025, with retail, social services, and beauty care sectors increasing by 4.56%, 4.61%, and 1.04% respectively, outperforming the Shanghai Composite Index which rose by 1.91% [14][17]. - Key events include the strategic investment of 3.4 billion yuan by Jianbo Biological into Yangshengtang, and the successful IPO of Yingtong Holdings on the Hong Kong Stock Exchange [3][28]. Summary by Sections Market Performance - The retail, social services, and beauty care sectors ranked 9th, 8th, and 24th among 31 primary industries, with notable increases in sub-sectors such as education, professional chains, and trade, which rose by 7.47%, 7.42%, and 5.2% respectively [14][17]. Key Industry Data and News - In the beauty care sector, significant developments include the entry of Kefu Mei into Malaysia's Watsons, becoming the first Chinese efficacy skincare brand in the region, and the announcement by the National Medical Products Administration regarding the management of cosmetic raw materials [23][24]. - Jianbo Biological's restructuring of its collagen product to a medical device category and the successful listing of Yingtong Holdings are also noteworthy [3][24]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Ltd., Juzhi Biological, Marubi Biological, Runben Co., Ltd., Proya, Chaohongji, Blukoo, and Furuida as potential investment targets within the highlighted sectors [5][29].

或许你已经发现，走进家里小区楼下的药店，第一眼看到的可能不是药品，而是薇诺娜、可复 美、绽妍等品牌的护肤产品，这一幕正悄然成为中国药店的"新常态"。 近日，福瑞达生物公布了年内覆盖1 0个千万级OTC连锁的大计划。无独有偶，百雀羚也于年 初宣布正式入驻北京同仁堂渠道。随着线上红利逐渐见顶，不少品牌开始瞄准线下OTC专业渠 道掘金。 《FBe a u t y未来迹》经过调研发现，美妆在OTC渠道的生意，比起未开发的蓝海，更像是一支 蓄势待发的弓箭。在已经跑出薇诺娜这个十亿级销售规模美妆品牌的情况下，依旧还有巨大的 想象空间。 OTC渠道可以说是目前在线下分布最广的一类渠道，正如居民楼附近不一定会有化妆品店，但 一定会有药店，而这不是错觉。 根据薇诺娜母公司贝泰妮集团发布的2 0 2 4年上半年财报，OTC分销渠道销售模式实现营业收 入人民币3 5 , 4 7 0 . 1 4万元，约占主营业务收入1 2 . 7 1%，同比增长约2 0 . 0 1%。 按照这一增速， 薇诺娜在OTC的年销售规模大概率已经迈过1 0亿门槛。 据公开资料，薇诺娜从2 0 1 6年开始与连锁药房合作，彼时市场体量只有5 0万左右；8年后 ...